<DOC>
	<DOCNO>NCT00733174</DOCNO>
	<brief_summary>Subjects impair glucose tolerance randomize either rosiglitazone placebo 18 month period . The study look baseline , 12 month 18 month data exercise tolerance , coronary artery calcification diabetes indicator .</brief_summary>
	<brief_title>Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Subjects must sign informed consent participate study . Male female adult age 2575 year . Female subject must postmenopausal ( i.e. , &gt; 6 month without menstrual period ) , surgically sterile , use effective barrier contraceptive measure ( IntraUterine Device ( IUD ) , diaphragm spermicide condom spermicide ) . Women childbearing potential must use effective barrier contraceptive measure least 1 month prior visit 1 , continue use contraceptive method study 30 day discontinue study medication . Female subject childbearing potential must negative urine pregnancy test . Subjects must FPG &lt; 126 mg/dL Screening 1 AND Screening 2 , Cpeptide &gt; 2.0 ng/mL HbA1c &lt; 6.5 % . Subjects must Body Mass Index 2540 ( must &lt; 300 lb ) . Subjects must 2 hour postprandial glucose 140199 mg/dL Screening 1 AND Screening 2 . If 2 hour postprandial glucose result 130139 mg/dL Screening 2 , subject allow repeat OGTT . Women lactate , pregnant , plan become pregnant study exclude . Women use hormone contraception hormone replacement therapy exclude . Subjects clinically significant abnormality identify Screening physical examination , laboratory test , electrocardiogram , judgment Investigator , would preclude safe completion study also exclude . Use investigational agent participation investigational study study period allow . Patients also exclude presence clinically significant hepatic disease patient LFT level &gt; 2 time upper limit normal laboratory range Subjects document history significant hypersensitivity ( e.g. , difficulty swallowing , difficulty breathing , tachycardia skin reaction ) thiazolidinediones Subjects contraindication rosiglitazone Presence unstable severe ( New York Heart AssociationNYHA class 3 4 ) angina , include angina require continual nitrate treatment symptomatic relief , coronary insufficiency Subjects HYHA class 3 4 congestive heart failure require drug therapy ; systolic blood pressure &gt; 160 mmHg diastolic blood pressure &gt; 100 mmHg History cancer ( except nonmelanomatous skin carcinoma ) Active alcohol drug abuse within last 6 month Subjects chronic disease require periodic intermittent treatment oral intravenous corticosteroid Subjects unable understand dose direction swallow study medication Subjects currently smoke Subjects unable adhere protocol requirement . Persons angina cardiac pulmonary symptom would potentially limit exercise performance exclude . Persons take prescription overthecounter weight loss medication person weight loss program ongoing weight loss , start intensive exercise program within 30 day screen also exclude .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>IGT</keyword>
</DOC>